BRIEF published on 11/04/2024 at 11:51, 1 year 11 months ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 11 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 2 years ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
PRESS RELEASE published on 10/11/2024 at 17:45, 2 years ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 2 years 3 months ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 07/09/2024 at 20:45, 2 years 3 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its 2023 annual results, financial highlights, and financing outlook. Annual General Meeting scheduled for September 13, 2024 Annual General Meeting Financial Highlights 2023 Annual Results ACTICOR BIOTECH Financing Outlook
BRIEF published on 05/15/2024 at 11:20, 2 years 4 months ago Results of the ACTISAVE study and future perspectives of ACTICOR BIOTECH Stroke Treatment ACTICOR BIOTECH Glenzocimab ESOC 2024 ACTISAVE Study
PRESS RELEASE published on 05/15/2024 at 11:15, 2 years 4 months ago Inside Information / Other news releases ACTICOR BIOTECH presents main results of phase 2/3 ACTISAVE study on stroke treatment at ESOC 2024, targeting specific subgroups for potential benefits Stroke Treatment ACTICOR BIOTECH ESOC 2024 ACTISAVE Study Patient Subgroups
Published on 10/13/2026 at 14:00, 20 minutes ago Orogen Royalties Enters into Agreement to Sell the Slaughterhouse Copper-Gold Project to Seabridge Gold
Published on 10/13/2026 at 14:00, 20 minutes ago Fermi Signs Credit Support Agreement with AMD and Announces Partnership
Published on 10/13/2026 at 13:30, 50 minutes ago British Columbia Court Declares The Helix Resources Joint Venture on The Gold Basin Property is Set Aside and is Unenforceable
Published on 10/13/2026 at 13:30, 50 minutes ago Digi Power X Announces $200 Million Debt Financing Commitment to Support Completion of Alabama AI Data Center and Provides Expansion Update
Published on 10/13/2026 at 13:01, 1 hour 19 minutes ago CoTec Holdings Corp. Notes HyproMag USA Secures Power and Advances Project Readiness for Texas Rare Earth Magnet Recycling and Manufacturing Hub
Published on 10/13/2026 at 14:05, 14 minutes ago IDC Raises 2029 Forecast for OCP-Recognized Infrastructure Spending by 2.7x to $800 Billion
Published on 10/13/2026 at 14:00, 20 minutes ago Eckert & Ziegler and TerThera Sign Supply Agreement to Bring Next-Generation GMP Terbium-161 Radiopharmaceutical Therapies to Brazilian Patient
Published on 10/13/2026 at 13:14, 1 hour 5 minutes ago EQS-Adhoc: ElringKlinger raises 2026 full-year revenue guidance
Published on 10/13/2026 at 09:04, 5 hours 15 minutes ago Peru Is Recognized as “South America's Leading Destination” at the World Travel Awards
Published on 10/12/2026 at 17:59, 20 hours 20 minutes ago Reporting on share buyback transactions carried out between October 7 and October 9, 2026
Published on 10/12/2026 at 17:45, 20 hours 35 minutes ago Declaration of transactions on own shares from October 5, 2026 to October 11, 2026
Published on 10/12/2026 at 15:47, 22 hours 32 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of September 30, 2026
